Skip to main content
. 2021 Jul 3;22(13):7195. doi: 10.3390/ijms22137195

Figure 5.

Figure 5

Effects of stage-specific transcriptional activation of Amelx on ameloblast differentiation of Amelx-iPSCs. (A) Diagram of the established stepwise induction protocol. (B–D) Cell morphology of Amelx-iPSCs on day 5 (B), 10 (C), and 17 (D) with or without Dox treatment during stage 1 (B), stage 2 (C) or stage 3 (D). Scale bars: 200 μm. (E–G) Gene expression of stemness (Oct4), surface ectoderm (Krt18), non-neural ectoderm (Dlx3), neural ectoderm (Sox1), mesoderm (Brachyury), endoderm (Sox17) DEC (Krt14, p75, and tuftelin), and ameloblast (Amelx, Ambn, and enamelin) markers in Amelx-iPSCs on day 5 (E), 10 (F), and 17 (G) with or without Dox treatment during stage 1 (E), stage 2 (F), or stage 3 (G) as determined by semi-quantitative RT-PCR analysis. (H-I) Expression of KRT14 and AMBN in Amelx-iPSCs on day 10 (H) and 17 (I) with or without Dox treatment during stage 2 (H) or stage 3 (I) as determined by Western blotting. β-actin was used as an internal control. (J) Alizarin Red S (ARS) staining on day 17 for Amelx-iPSCs with or without Dox treatment during stage 3. Scale bars: 1 cm and 100 μm for upper and lower panels, respectively.